Receptor activator of nuclear factor κB ligand (RANKL): another link between breast and bone
- 1 January 2001
- journal article
- review article
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 12 (1), 2-4
- https://doi.org/10.1016/s1043-2760(00)00351-9
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland DevelopmentCell, 2000
- Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling OsteoclastogenesisThe Journal of Experimental Medicine, 2000
- Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infectionJournal of Clinical Investigation, 2000
- Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandNature, 1999
- Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactationOncogene, 1999
- Prolactin Controls Mammary Gland Development via Direct and Indirect MechanismsDevelopmental Biology, 1999
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999
- OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature, 1999
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997
- Cyclin D1 provides a link between development and oncogenesis in the retina and breastCell, 1995